27,684 findings
- Energy balanceStrong
The additional quality-adjusted life years (QALYs) gained by ILI were not statistically significant, with values of 0.17 and 0.16 measured by SF-6D and Feeling Thermometer, respectively.
The lack of statistically significant QALY gains suggests that intensive lifestyle interventions may not provide additional health benefits over standard education.
Refutes 2020 - CellularStrong
Akt Thr(308) phosphorylation was unaltered after either bout of exercise.
Neither endurance nor resistance exercise affects Akt Thr(308) phosphorylation.
Supports 2006 - Energy balanceStrong
No significant findings emerged in men and women separately, in the African-American subset, or for the 8-10 week outcomes.
Results may not be generalizable across all demographics, highlighting the need for tailored approaches.
Refutes 2021 - HormonalStrong
GLP-1RAs can induce gastric food retention, increasing the risk for pulmonary aspiration during anesthesia.
Clinicians should consider the risk of pulmonary aspiration when using GLP-1RAs in patients undergoing anesthesia.
Supports 2025New - Energy balanceStrong
Management of GLP-1RA adverse events lacks evidence-based support.
Healthcare providers should be cautious in applying management strategies for GLP-1RA adverse events due to the lack of evidence.
Refutes 2025New - Energy balanceStrong
Rifampicin inhibits body weight gain in high-fat diet-fed mice.
Rifampicin may be considered as a potential treatment for obesity in high-fat diet contexts.
Supports 2025New - CellularStrong
Rifampicin enhances lipolysis and suppresses lipogenesis in adipocytes.
Rifampicin may be useful in promoting fat loss by altering lipid metabolism.
Supports 2025New - MolecularStrong
The effects of rifampicin on obesity are mediated through Sirt6.
Targeting Sirt6 may enhance the effectiveness of rifampicin in obesity treatment.
Supports 2025New - MolecularStrong
Novel drug candidates like dual amylin and calcitonin receptor agonists (DACRAs) have insulin-sensitizing properties through a weight-independent action.
DACRAs may offer new treatment options for improving insulin sensitivity.
Supports 2025New - Energy balanceStrong
Mice receiving NN501 display a more gradual weight regain and no compensatory hyperphagic response after treatment cessation.
NN501 may help in maintaining weight loss without the rebound effects seen with other treatments.
Supports 2025New - NeuralStrong
GLP-1 receptor agonists (GLP-1RAs) may have neuroprotective and neurotrophic effects in ALS models.
GLP-1RAs may be considered for further investigation in ALS treatment.
Supports 2026New - Energy balanceStrong
Current clinical evidence does not demonstrate therapeutic benefit of GLP-1RAs in ALS.
Clinicians should be cautious in prescribing GLP-1RAs for ALS due to lack of evidence.
Refutes 2026New - CellularStrong
Obesity is characterized by adipose tissue dysfunction, insulin resistance, chronic low-grade inflammation, and gut microbiota dysbiosis.
Understanding these characteristics can help in developing targeted interventions for obesity.
Supports 2025New - Metabolic adaptationStrong
Prior GLP-1 agonist use is not associated with in-hospital mortality in critically ill patients.
Clinicians may consider that prior GLP-1 agonist use does not adversely affect mortality in critically ill patients.
Refutes 2025New - Metabolic adaptationStrong
Prior GLP-1 agonist use is not associated with hospital length of stay in critically ill patients.
Clinicians may conclude that prior GLP-1 agonist use does not prolong hospital stays for critically ill patients.
Refutes 2025New - Metabolic adaptationStrong
Prior GLP-1 agonist use is not associated with ICU length of stay in critically ill patients.
Clinicians may determine that prior GLP-1 agonist use does not affect ICU length of stay for critically ill patients.
Refutes 2025New - CellularStrong
Greater achieved weight loss during the landmark period did not show a consistent association with lower post-landmark cardiovascular risk.
Weight loss alone may not be sufficient to reduce cardiovascular risk, emphasizing the importance of medication dosage.
Refutes 2026New - Energy balanceStrong
Women's adjusted odds of diagnosis were far higher than men's (95% confidence interval 1.66-1.75).
Healthcare providers should consider gender disparities in obesity diagnosis when assessing patients.
Supports 2025New - Metabolic adaptationStrong
Liraglutide did not have measurable effects on lean or bone tissue over the 18-day period.
Liraglutide may not affect muscle or bone mass in the short term.
Supports 2025New - Energy balanceStrong
Obesity is defined as a BMI of more than 30 kg/m2 and is a prevalent chronic disease.
Healthcare practitioners should recognize obesity as a significant health challenge.
Supports 2022 - Energy balanceStrong
The incidence of obesity has nearly trebled since 1975.
Public health initiatives must address the rising rates of obesity.
Supports 2022 - MolecularStrong
The comparative bioavailability of semaglutide following oral administration (3 mg) relative to subcutaneous administration (0.25 mg) is 0.66%.
Practitioners should note the lower bioavailability of oral semaglutide compared to subcutaneous administration.
Supports 2025New - MolecularStrong
The pharmacokinetics of semaglutide was characterized following the administration of low subcutaneous and oral doses.
Understanding the pharmacokinetics can inform dosing strategies for semaglutide.
Supports 2025New - CellularStrong
The study drug was well tolerated, and no serious adverse events were reported.
Practitioners can consider semaglutide safe for use in healthy individuals based on this study.
Supports 2025New